# Spero Therapeutics (SPRO) — Analyst Forecast

SPRO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/spro/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 0 | 1 | 0 | 1 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 14, 2026 | HC Wainwright & Co. | Maintained | Buy | $6.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Dec 20, 2024 | Evercore ISI Group | Downgraded | Outperform → In-Line | $5.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Nov 18, 2024 | TD Cowen | Downgraded | Buy → Hold | — |
| Nov 15, 2024 | Cantor Fitzgerald | Maintained | Overweight | — |
| Nov 4, 2024 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Aug 6, 2024 | Cantor Fitzgerald | Maintained | Overweight | — |
| Aug 6, 2024 | TD Cowen | Upgraded | Hold → Buy | — |
| May 16, 2024 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Apr 4, 2024 | Cantor Fitzgerald | Maintained | Overweight | — |
| Mar 18, 2024 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Sep 5, 2023 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Aug 14, 2023 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Aug 1, 2023 | HC Wainwright & Co. | Maintained | Buy | $6.00 |
| Jul 20, 2023 | HC Wainwright & Co. | Maintained | Buy | $6.00 |

## Frequently Asked Questions

### Is SPRO a buy, sell, or hold?

Analysts covering Spero Therapeutics currently average a Hold rating: 0 buy, 1 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on SPRO?

On Sep 14, 2026, HC Wainwright & Co. maintained Spero Therapeutics at Buy with a price target of $6.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).